The flu continues to pose a serious health risk in the United States, accounting for more than 35,000 deaths each year. Despite vaccination being the most effective preventive measure, existing shots, particularly those administered through injection, often fail to block the virus from establishing itself in the respiratory tract. New findings in Nature Immunology highlight a previously understudied group of immune cells in the lungs that could enhance vaccine performance.
Following infection or vaccination, the immune system generates specialized cells known as “memory” cells, which provide rapid protection against future exposures. In the lungs, a distinct subset called tissue-resident memory T cells serves as the first line of defense at the infection site. These cells are strategically positioned where viruses gain entry, enabling them to respond swiftly and limit viral spread. However, conventional flu vaccines, especially injected varieties, do not consistently generate strong immune memory in the airways, creating a critical gap in defense.
The research team examined how the immune system establishes and sustains these protective memory T cells. They uncovered that a specific type of monocyte, typically regarded as short-lived, can persist in lung tissue for months after flu exposure. These enduring cells contribute to immune memory by supporting the survival and function of memory T cells within the respiratory system.
Previously, immune memory was believed to rely primarily on T and B cells. This study overturns that assumption, demonstrating that innate immune cells, such as these monocytes, also play a lasting role. The findings further explain how these cells interact with T cells: they secrete a protein called galectin-1, which activates and maintains tissue-resident memory T cells over time.
When galectin-1 was incorporated into an experimental nasal flu vaccine in mice, the lung-based immune response became markedly stronger. This discovery points to a novel vaccine design approach.
Current flu vaccines, mostly delivered via injection into the muscle, effectively reduce severe illness but do not reliably prevent viral entry in the nose and lungs. Nasal vaccines seek to address this limitation by targeting immunity directly at infection sites, yet their results have varied. The study suggests that optimizing interactions between innate immune cells and memory T cells could significantly boost nasal vaccine outcomes.
Leave a Reply